Granules India
Drug Manufacturers - Specialty & Generic · GRANULES
Mid CapHealthcareHigh Growth
Pradeep Reddy
Chairman and Managing Director · Visionary
Company DNA
Performance-Driven
About
Granules India is a Mid Cap company in the Healthcare sector, listed on NSE as GRANULES. With a market cap of ₹14K Cr and revenue of ₹4K Cr, it is currently in the High Growth phase. Known for its Performance-Driven culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Known for highly aggressive operational efficiencies and growth-focused manufacturing targets. Its strategic mandate: As it scales its complex API and finished dosage production, the firm requires a leader focused on margin optimization and global regulatory compliance.
FAQ
What kind of company is Granules India?
Granules India is a Mid Cap Healthcare company (GRANULES) in the High Growth phase with a market cap of ₹14K Cr. It is classified as Performance-Driven in culture.
What is Granules India's culture and work environment like?
Granules India has a Performance-Driven culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Demanding Machine. Customer relationship style: B2B-Enterprise. Known for highly aggressive operational efficiencies and growth-focused manufacturing targets.
Who leads Granules India?
Granules India is led by Pradeep Reddy (Chairman and Managing Director), a Visionary leader with 48 years of experience.
What are Granules India's financials?
Granules India reported revenue of ₹4K Cr in FY25 with a 5-year revenue CAGR of 6.1%. Operating margin: 16.4%. Market cap: ₹14K Cr.
Culture & Strategy
CulturePerformance-Driven
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeDemanding Machine
BrandValue-Champion
LifecycleHigh Growth
Known for highly aggressive operational efficiencies and growth-focused manufacturing targets.
Mandate
As it scales its complex API and finished dosage production, the firm requires a leader focused on margin optimization and global regulatory compliance.
As it scales its complex API and finished dosage production, the firm requires a leader focused on margin optimization and global regulatory compliance.
Financials
Revenue FY25₹4K Cr
PAT FY25₹502 Cr
Rev CAGR 5Y6.1%
OPM16.4%
NPM11.3%
ROE13.5%
ROCE17.2%
P/E25
Fwd P/E18.6
P/B3.4
D/E45.4
Mkt Cap₹14K Cr
Promoter39.3%
Institutional22.4%
Similar Culture
Could You Lead Granules India?
Take the Genome Benchmark →